Italy
Italy

Time filter

Source Type

Oliveira M.C.,University of Sao Paulo | Labopin M.,EBMT | Henes J.,Medizinische Universitatsklinik Abt Ii | Moore J.,St Vincents Hospital | And 16 more authors.
Bone Marrow Transplantation | Year: 2016

This EBMT Autoimmune Disease Working Party study aimed to evaluate the influence of CD34+ positive graft selection (CD34+) on the outcome of systemic sclerosis (SSc) patients after autologous hematopoietic stem cell transplantation (AHSCT). Clinical and laboratory data from 138 SSc patients at diagnosis, before and after AHSCT were retrospectively analyzed. CD34+ selection was performed in 47.1% (n=65) patients. By multivariate analysis adjusting for all factors differing between the two groups (without or with CD34+), there was no statistically significant difference in terms of overall survival (hazard ratio (HR): 0.98, 95% confidence interval (CI) 0.40-2.39, P=0.96), PFS (HR: 1.55, 95% CI 0.83-2.88, P=0.17) and incidence of relapse or progression (HR: 1.70, 95% CI 0.85-3.38, P=0.13). We demonstrate that CD34+ does not add benefit to the outcome of SSc patient treated with AHSCT. These findings should be further confirmed by prospective randomized trials. © 2016 Macmillan Publishers Limited.


PubMed | Institute of Hematology and Transfusion Medicine, EBMT Data Office Leiden, Queen's University of Belfast, Queen Elizabeth Hospital and 18 more.
Type: Journal Article | Journal: Haematologica | Year: 2016

POEMS syndrome is a rare para-neoplastic syndrome secondary to a plasma cell dyscrasia. Effective treatment can control the disease-related symptom complex. We describe the clinical outcome of autologous stem cell transplantation for patients with POEMS syndrome, determining the impact of patient- and disease-specific factors on prognosis. One hundred and twenty-seven patients underwent an autologous stem cell transplantation between 1997-2010 with a median age of 50 years (range 26-69 years). Median time from diagnosis to autologous stem cell transplantation was 7.5 months with 32% of patients receiving an autologous stem cell transplantation more than 12 months from diagnosis. Engraftment was seen in 97% patients and engraftment syndrome was documented in 23% of autologous stem cell transplantation recipients. Hematologic response was characterized as complete response in 48.5%, partial response in 20.8%, less than partial repsonse in 30.7%. With a median follow up of 48 months (95%CI: 38.3, 58.6), 90% of patients are alive and 16.5% of patients have progressed. The 1-year non-relapse mortality was 3.3%. The 3-year probabilities of progression-free survival and overall survival are 84% and 94%, respectively, with 5-year probabilities of progression-free survival and overall survival of 74% and 89%. In a cohort of graft recipients, detailed organ-specific symptom response demonstrated clear symptom benefit after autologous stem cell transplantation especially in relation to neurological symptom control. The data analyzed in this study demonstrate the clinical utility of autologous stem cell transplantation for patients with POEMS syndrome.


PubMed | Charité - Medical University of Berlin, University of Ferrara, University Paris Diderot, St Vincents Hospital and 13 more.
Type: Journal Article | Journal: Bone marrow transplantation | Year: 2016

This EBMT Autoimmune Disease Working Party study aimed to evaluate the influence of CD34+ positive graft selection (CD34+) on the outcome of systemic sclerosis (SSc) patients after autologous hematopoietic stem cell transplantation (AHSCT). Clinical and laboratory data from 138 SSc patients at diagnosis, before and after AHSCT were retrospectively analyzed. CD34+ selection was performed in 47.1% (n=65) patients. By multivariate analysis adjusting for all factors differing between the two groups (without or with CD34+), there was no statistically significant difference in terms of overall survival (hazard ratio (HR): 0.98, 95% confidence interval (CI) 0.40-2.39, P=0.96), PFS (HR: 1.55, 95% CI 0.83-2.88, P=0.17) and incidence of relapse or progression (HR: 1.70, 95% CI 0.85-3.38, P=0.13). We demonstrate that CD34+ does not add benefit to the outcome of SSc patient treated with AHSCT. These findings should be further confirmed by prospective randomized trials.


HELENA, Mont., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) (the “Company”), holding company for Opportunity Bank of Montana (the “Bank”), today announced that it has sold $10 million in senior unsecured notes (the “Notes”) in a private placement offering.  The Notes were issued on February 13, 2017, bear a fixed rate of interest of 5.75% per annum, payable semi-annually, and mature on February 15, 2022. The Company estimates that the net cash proceeds from the sale of the Notes will be approximately $9.8 million.  The Company intends to use the net proceeds from the offering for general corporate purposes, including but not limited to, contribution of capital to the Bank to support both organic growth as well as opportunistic acquisitions.  The Notes issued by the Company also received a rating of “A-” from Egan-Jones Rating Company. "This growth capital gives us an opportunity to continue to build out our business plan of strong organic growth, and meet the growing demand from our customers and communities,” said Peter J. Johnson, President and Chief Executive Officer of the Company. “Senior unsecured Notes are a cost effective way to provide funding for our subsidiary bank.  We are also very pleased to have obtained a strong rating from Egan-Jones.” This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.  The above referenced securities offered and sold by the Company have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold absent registration or an exemption from registration. Brean Capital, LLC in New York served as placement agent for the private offering. Holland & Knight LLP served as the Company's legal counsel and Schulte, Roth and Zabel LLP served as Brean's legal counsel in this offering. Eagle Bancorp Montana, Inc. is a bank holding company headquartered in Helena, Montana and is the holding company of Opportunity Bank of Montana, a community bank established in 1922 that serves consumers and small businesses in southern Montana through 13 banking offices. Additional information is available on the bank’s website at www.opportunitybank.com. Shares of Eagle Bancorp Montana, Inc. common stock are traded on the NASDAQ Global Select Market under the symbol “EBMT”. The statements contained herein that are not historical facts are forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company.  Such statements involve inherent risks and uncertainties, many of which are difficult to predict and are generally beyond the control of the Company.  There can be no assurance that future developments affecting the Company will be the same as those anticipated by management.  The Company cautions readers that a number of important factors could cause actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements.  These risks and uncertainties include, but are not limited to, the following: the strength of the United States economy in general and the strength of the local economies in which we conduct operations; the effects of, and changes in, trade, monetary and fiscal policies and laws, including interest rate policies of the Board of Governors of the Federal Reserve System; inflation, interest rate, market and monetary fluctuations; the timely development of competitive new products and services and the acceptance of these products and services by new and existing customers; the willingness of users to substitute competitors’ products and services for the Company’s products and services; the impact of changes in financial services policies, laws and regulations (including the Dodd-Frank Wall Street Reform and Consumer Protection Act) and of governmental efforts to restructure the U.S. financial regulatory system; technological changes; the effect of acquisitions that the Company may make, if any, including, without limitation, the failure to achieve the expected revenue growth and/or expense savings from its acquisitions; changes in the level of the Company’s nonperforming assets and charge-offs; the supply and value of Montana real estate, both residential and commercial; the effect of changes in accounting policies and practices, as may be adopted from time-to-time by bank regulatory agencies, the Securities and Exchange Commission (“SEC”), the Public Company Accounting Oversight Board, the Financial Accounting Standards Board or other accounting standards setters; possible other-than-temporary impairment of securities held by us; changes in consumer spending, borrowing and savings habits; ability to attract deposits and other sources of liquidity; changes in the financial performance and/or condition of our borrowers; changes in the competitive environment among financial and bank holding companies and other financial service providers; unanticipated regulatory or judicial proceedings; and the Company’s ability to manage the risks involved in the foregoing.  Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the 2015 Annual Report on Form 10-K of Eagle Bancorp Montana, Inc. filed with the SEC and available at the SEC’s Internet site (http://www.sec.gov). The Company specifically disclaims any obligation to update any factors or to publicly announce the result of revisions to any of the forward-looking statements included herein to reflect future events or developments.


News Article | November 7, 2016
Site: www.prnewswire.co.uk

Eleven Presentations Evaluating Marketed and Investigational Compounds for Hepatic Veno-Occlusive Disease (VOD) and Acute Myeloid Leukemia (AML) Presentations Include a Sub-Analysis of Phase 3 Data for Vyxeos (CPX-351), an investigational product for the treatment of AML Patients DUBLIN, Nov. 7, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that eleven abstracts, including four oral presentations, supporting the company's hematology and oncology portfolio will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, December 3-6, 2016. "The data presentations at ASH reflect our efforts in advancing our diversified pipeline of programs in hematology and oncology, including rare blood disorders such as acute lymphoblastic leukemia (ALL) and AML, and in complications of hematopoietic stem-cell transplantation (HSCT) such as hepatic VOD," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer at Jazz Pharmaceuticals. "Of note, we look forward to sharing a post-hoc sub-analysis of Phase 3 survival data following allogeneic HSCT in older high-risk AML patients that compares CPX-351, also known as Vyxeos, with the standard of care." The following oral and poster presentations focusing on Defitelio® (defibrotide sodium) injection, Erwinaze® (asparaginase Erwinia chrysanthemi) and CPX-351(cytarabine and daunorubicin liposome injection) will be presented at ASH. Additionally, one Jazz-sponsored Investigator Initiated Research poster presentation focusing on CPX-351 as an investigational agent for the treatment of AML will be presented at ASH. Full details of the ASH 2016 annual meeting can be found here (http://www.hematology.org/Annual-Meeting/) and abstracts can be found here (https://ash.confex.com/ash/2016/webprogram/start.html). About Defitelio1 In the U.S., Defitelio® (defibrotide sodium) injection 80mg/mL received FDA marketing approval on March 30, 2016 for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) and is the first and only FDA-approved therapy for patients with this rare, potentially fatal complication. Defitelio is contraindicated in patients currently taking anticoagulants or fibrinolytics and in patients who are allergic to Defitelio or any of its ingredients. Defitelio may increase the risk of bleeding and should be withheld or stopped if significant bleeding occurs. Patients should be monitored for allergic reactions, especially if there is a history of previous exposure to Defitelio. The most common side effects of Defitelio are decreased blood pressure, diarrhea, vomiting, nausea and nose bleeds. Please see full for Defitelio. (https://defitelio.com/DefitelioPI.pdf) In Europe, defibrotide is marketed under the name Defitelio®▼(defibrotide). In October 2013, the European Commission granted marketing authorization to Defitelio under exceptional circumstances for the treatment of severe VOD in patients undergoing HSCT therapy. It is the first and only approved treatment in Europe for severe VOD. In Europe, Defitelio is indicated in patients over one month of age. It is not indicated in patients with hypersensitivity to defibrotide or any of its excipients or with concomitant use of thrombolytic therapy. ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system found under section 4.8 of the SmPC. (http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002393/human_med_001646.jsp) About VOD HSCT is an aggressive, potentially curative procedure to treat patients with malignant and non-cancerous hematologic disorders such as leukemia, lymphoma and aplastic anemia, and congenital immunodeficiency and autoimmune disorders.2 VOD is a rare complication of HSCT, which occurs in approximately 9-14% of HSCT patients.3,4 Hepatic VOD, also known as SOS, is an early and life-threatening complication affecting the sinusoidal endothelial cells of the liver, which can typically occur within the first 21 days following HSCT.4,5 Hepatic VOD progresses to multi-organ dysfunction in approximately 30-50% of cases.5 VOD with multi-organ dysfunction (MOD) is associated with an overall mortality (death) rate of 84%.3 MOD is characterized by the presence of renal or pulmonary dysfunction.6,7 VOD is often characterized by sudden weight gain, hepatomegaly (abnormally enlarged liver), and elevated bilirubin.6,7 About Erwinaze Erwinaze® (asparaginase Erwinia chrysanthemi) is currently approved in the U.S. for administration via intramuscular injection or via intravenous infusion in conjunction with chemotherapy. It is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.8 Erwinaze is derived from the bacterium Erwinia chrysanthemi and is therefore immunologically distinct from E. coli-derived asparaginase and suitable for patients with hypersensitivity to E. coli-derived treatments9. Outside of the U.S., Erwinaze is sold under the name Erwinase®. Please consult local labeling for product information specific to your country. Erwinaze is contraindicated in patients who have had serious allergic reactions to Erwinaze, or had serious swelling of the pancreas, serious blood clots, or serious bleeding with past L-asparaginase treatment. Erwinaze should be discontinued if any of the following occur: serious allergic reactions, including a feeling of tightness in the throat, unusual swelling/redness in the throat and/or tongue, or trouble bleeding; or severe inflammation of the pancreas. Glucose intolerance has been reported, which in some cases may be irreversible. If blood clots of bleeding occur, discontinue Erwinaze until symptoms resolve. The most common side effects of Erwinaze are allergic reactions, too much sugar in the blood, fever, swelling of the pancreas, local reactions (swelling, rash, etc. where the needle entered the skin), vomiting, nausea, blood clots, liver problems, stomach pain/discomfort, and diarrhea. Please see full Prescribing Information for Erwinaze. (https://www.jazzpharma.com/wp-content/uploads/2016/01/erwinaze-en-PI.pdf) About Vyxeos (CPX-351) CPX-351 (cytarabine and daunorubicin liposome injection) is an investigational product being evaluated for the treatment of AML and is a combination of cytarabine and daunorubicin encapsulated within a nano-scale liposome at a 5:1 molar ratio. The proposed trade name, Vyxeos™, is conditionally approved by the FDA and is subject to confirmation upon approval of the NDA. CPX-351 was granted orphan drug status by the FDA and the European Commission for the treatment of acute myeloid leukemia. CPX-351 was granted Breakthrough Therapy Designation for the treatment of adults with therapy-related AML or AML with myelodysplasia-related changes and was also granted Fast Track designation by the FDA for the treatment of older patients with secondary AML. On October 3, 2016 Jazz announced the initiation of a rolling submission of a New Drug Application (NDA) to the FDA, seeking marketing approval of CPX-351 for the treatment of AML. About Acute Myeloid Leukemia Acute myeloid leukemia (AML) is a rapidly progressing and life-threatening blood cancer that rises in frequency with age.16 The American Cancer Society estimates that there will be 19,950 new cases of AML and 10,430 deaths from AML in the U.S. in 2016.10 In the European Union, the number of new cases is estimated to be 20,100 in 2016.11 The median age at diagnosis is 67 and with rising age there is progressive worsening of prognosis.10,12 Advancing age is associated with increasing risk of specific chromosomal/mutational changes and risk of pre-malignant marrow disorders which give rise to more aggressive and less responsive forms of AML.13,14 As patients age there is also reduced tolerance for intensive chemotherapy.15 As a consequence, advances in supportive care, intensive chemotherapy, and bone marrow transplantation have primarily benefitted younger patients with approximately one third of patients 18-60 years of age achieving cure.13,15 Older patients have not achieved higher rates of cure or improved upon a 5-year survival rate of 10-20% in spite of 40 years of research.15,16 About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com. References: 1 Defitelio (defibrotide sodium) [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; March 30, 2016. 2 Ikehara S. New strategies for BMT and organ transplantation. Int J Hematol. 2002;76(Suppl 1):161-4. 3 Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-168. 4 Tsirigotis PD, Resnick IB, Avni B, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transplant. 2014;49(11):1389-1392. 5 Carreras E, Díaz-Beyá M, Rosiñol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood MarrowTransplant. 2011;17(11):1713-1720. 6 Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Brit J Haematol. 2015 Feb.; 168 (4); 481-91. 7 Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno‐occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781‐789. 8 Erwinaze® (asparaginase Erwinia chrysanthemi) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc., December 2014. 9 Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15; 117(2): 238–249. 10 American Cancer Society. Leukemia--Acute Myeloid (Myelogenous). Detailed Guide. What are the key statistics about acute myeloid leukemia? http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-key-statistics. Last revised February 22, 2016. Accessed November 3, 2016. 11 Decisions Research Group. Acute Myeloid Leukemia. https://decisionresourcesgroup.com/report/141439-biopharma-acute-myeloid-leukemia/. Published November 2015. Accessed November 3, 2016. 12 Baer M, George S, Sanford B, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25(5):10.1038/leu.2011.9. doi:10.1038/leu.2011.9. 13 Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013 Feb 9;381(9865):484-495. 14 Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-474. 15 Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98-117. 16 Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol. 2016 May;27(5):770-778.


Baronciani D.,Ematologia e Centro Trapianti | Angelucci E.,Ematologia e Centro Trapianti | Potschger U.,Medical University of Vienna | Gaziev J.,International Center for Transplantation in Thalassemia and Sickle Cell Anemia | And 15 more authors.
Bone Marrow Transplantation | Year: 2016

Allogeneic hemopoietic stem cell transplantation (HSCT) is the only method currently available to cure transfusion-dependent thalassemia major that has been widely used worldwide. To verify transplantation distribution, demography, activity, policies and outcomes inside the European Group for Blood and Marrow Transplantation (EBMT), we performed a retrospective non-interventional study, extracting data from the EBMT hemoglobinopathy prospective registry database. We included 1493 consecutive patients with thalassemia major transplanted between 1 January 2000 and 31 December 2010. In total, 1359 (91%) transplants were performed on patients <18 years old, 1061 were from a human leukocyte Ag-identical sibling donor. After a median observation time of 2 years, the 2-year overall survival (OS) and event-free survival (EFS; that is, thalassemia-free survival) were 88±1% and 81±1%, respectively. Transplantation from a human leukocyte Ag-identical sibling offered the best results, with OS and EFS of 91±1% and 83±1%, respectively. No significant differences in survival were reported between countries. The threshold age for optimal transplant outcomes was around 14 years, with an OS of 90-96% and an EFS of 83-93% when transplants were performed before this age. Allogeneic HSCT for thalassemia is a curative approach that is employed internationally and produces excellent results. © 2016 Macmillan Publishers Limited.


Fox C.P.,University of Nottingham | Boumendil A.,EBMT | Schmitz N.,EBMT | Finel H.,EBMT | And 13 more authors.
Leukemia and Lymphoma | Year: 2015

Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease. © 2015 Informa UK, Ltd.


HELENA, Mont., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Eagle Bancorp Montana, Inc. (NASDAQ:EBMT), (the “Company,” “Eagle”), the holding company of Opportunity Bank of Montana, today reported net income increased 240% to $1.8 million, or $0.46 per diluted share, in the third quarter of 2016, compared to $521,000, or $0.14 per diluted share, in the third quarter a year ago.  In the preceding quarter, Eagle earned $1.3 million, or $0.32 per diluted share.  In the first nine months of 2016, net income increased 117% to $3.7 million, or $0.95 per diluted share, compared to $1.7 million, or $0.44 per diluted share, in the first nine months of 2015. Eagle’s board of directors declared a regular quarterly cash dividend of $0.08 per share.  The dividend will be payable December 2, 2016 to shareholders of record November 11, 2016.  The current annualized yield is 2.20% at recent market prices. “We produced record operating results during the quarter, with strong revenue growth, robust mortgage production, double digit annualized loan growth and an improved net interest margin,” said Peter J. Johnson, President and CEO.  “Our focus on gathering core deposits, growing the loan portfolio and expanding our customer base throughout Montana continues to gain momentum.  We continue to improve upon our performance metrics with a return on average assets of 1.07%, a return on average equity of 11.82% and an improved efficiency ratio of 69.70%, for the third quarter of 2016. This solid financial performance is a reflection of the hard work of our employees and their commitment to our customers.” Third Quarter 2016 Highlights (at or for the three month period ended September 30, 2016, except where noted) “Loan production remained solid, as did the regional economy, and we continue to see significant potential for growth in our loan origination pipelines, particularly with commercial real estate and C&I loan segments,” said Johnson.  Total loans increased 4.0% to $461.5 million at September 30, 2016, compared to $443.9 million three months earlier and increased 17.9% compared to $391.5 million a year earlier. Eagle originated $101.2 million in new residential mortgages during the quarter, excluding construction loans, and sold $95.6 million in residential mortgages, with an average gross margin on sale of mortgage loans of approximately 3.30%.  This production compares to residential mortgage originations of $80.5 million in the preceding quarter with sales of $68.7 million. Commercial real estate loans increased 31.7% to $205.8 million at September 30, 2016, compared to $156.3 million a year earlier, while residential mortgage loans decreased 3.4% to $113.3 million compared to $117.3 million a year earlier.  Commercial loans increased 77.4% to $60.1 million, home equity loans increased 2.3% to $47.7 million and construction loans decreased 11.0% to $20.6 million, compared to a year ago. Eagle’s total deposits increased 7.1% to $515.3 million at September 30, 2016, compared to $481.1 million a year earlier and were up 1.3% compared to $508.9 million at June 30, 2016.  As of September 30, 2016, checking and money market accounts represent 51.5%, savings accounts represent 15.6%, and CDs comprise 32.9% of the total deposit portfolio. Total assets increased 10.3% to $674.5 million at September 30, 2016, compared to $611.4 million a year earlier and increased 1.7% compared to $663.3 million three months earlier.  Shareholders’ equity improved to $60.0 million at September 30, 2016, compared to $59.0 million three months earlier and $54.4 million one year earlier.  Tangible book value improved to $13.91 per share at September 30, 2016, compared to $13.63 per share at June 30, 2016 and $12.40 per share a year earlier. “Third quarter net interest margin improved 24 basis points compared to the preceding quarter and 27 basis points compared to the third quarter a year ago, primarily as a result of our strong loan growth,” Johnson said.  Eagle’s net interest margin was 3.55% in the third quarter, compared to 3.31% in the preceding quarter and 3.28% in the third quarter a year ago.  In the first nine months of the year, Eagle’s net interest margin was 3.40% compared to 3.36% in the same period one year ago.  Funding costs for the quarter were down one basis point while asset yields increased 26 basis points compared to a year ago.  The investment securities portfolio decreased to $133.8 million at September 30, 2016, compared to $147.5 million a year ago, which had a slight positive impact on the average yields on earning assets. Eagle’s third quarter revenues increased 15.6% to $10.1 million compared to $8.8 million in the preceding quarter and increased 37.6% compared to $7.3 million in the third quarter a year ago.  In the first nine months of 2016, revenues increased 19.8% to $26.6 million, compared to $22.2 million in the first nine months of 2015.  Net interest income before the provision for loan loss increased 9.7% to $5.4 million in the third quarter compared to $4.9 million in the preceding quarter, and increased 22.3% compared to $4.4 million in the third quarter a year ago.  In the first nine months of the year, net interest income increased 15.9% to $15.2 million, compared to $13.1 million in the first nine months of 2015. Primarily as a result of the net gain on sale of loans, noninterest income increased 23.2% to $4.7 million in the third quarter, compared to $3.8 million in the preceding quarter, and increased 61.0% compared to $2.9 million in the third quarter a year ago.  Year-to-date, noninterest income increased 25.6% to $11.4 million compared to $9.1 million in the first nine months a year ago.  Third quarter noninterest expenses were $7.2 million, compared to $6.7 million in the preceding quarter and $6.5 million in the year ago quarter.  Year-to-date, noninterest expense was up modestly to $20.4 million compared to $19.3 million in the first nine months of 2015. The third quarter provision for loan losses was $472,000, compared to $459,000 in the preceding quarter and $310,000 in the third quarter a year ago.  As of September 30, 2016, the allowance for loan losses represented 263.3% of nonperforming loans compared to 196.0% three months earlier and 216.6% a year earlier.  At September 30, 2016, nonperforming loans (NPLs) were $1.8 million, which was down 18.7% compared to $2.2 million three months earlier, and an increase compared to $1.5 million a year earlier. Eagle’s third quarter net charge-offs totaled $82,000, compared to $139,000 in the preceding quarter and $30,000 in the third quarter a year ago.  The allowance for loan losses was $4.7 million, or 1.01% of total loans at September 30, 2016, compared to $4.3 million, or 0.96% of total loans at June 30, 2016, and $3.2 million, or 0.83% of total loans a year ago. OREO and other repossessed assets was $513,000 at September 30, 2016, down slightly compared to $565,000 at June 30, 2016.  Nonperforming assets (NPAs), consisting of nonperforming loans, OREO and other repossessed assets, loans delinquent 90 days or more, and restructured loans, were $2.3 million at September 30, 2016, or 0.34% of total assets, compared to $2.7 million, or 0.41% of total assets three months earlier and $2.1 million, or 0.35% of total assets a year earlier. Eagle Bancorp Montana continues to be well capitalized with the ratio of shareholders’ equity to tangible asset of 10.10% at September 30, 2016.  (Shareholders’ equity, plus trust preferred securities and subordinated debt, less goodwill and core deposit intangible to tangible assets). Eagle Bancorp Montana, Inc. is a bank holding company headquartered in Helena, Montana and is the holding company of Opportunity Bank, a community bank established in 1922 that serves consumers and small businesses in Montana through 13 banking offices. Additional information is available on the bank’s website at www.opportunitybank.com.  The shares of Eagle Bancorp Montana, Inc. are traded on the NASDAQ Global Select Market under the symbol “EBMT.” This release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," and "potential." These forward-looking statements include, but are not limited to statements of our goals, intentions and expectations; statements regarding our business plans, prospects, growth and operating strategies; statements regarding the asset quality of our loan and investment portfolios; and estimates of our risks and future costs and benefits. These forward-looking statements are based on current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. These factors include, but are not limited to, changes in laws or government regulations or policies affecting financial institutions, including changes in regulatory fees and capital requirements; general economic conditions, either nationally or in our market areas, that are worse than expected; competition among depository and other financial institutions; loan demand or residential and commercial real estate values in Montana; inflation and changes in the interest rate environment that reduce our margins or reduce the fair value of financial instruments; adverse changes in the securities markets; and other economic, governmental, competitive, regulatory and technological factors that may affect our operations. Because of these and other uncertainties, our actual future results may be materially different from the results indicated by these forward-looking statements. All information set forth in this press release is current as of the date of this release and the company undertakes no duty or obligation to update this information.


HELENA, Mont., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Eagle Bancorp Montana, Inc. (NASDAQ:EBMT), (the “Company,” “Eagle”), the holding company of Opportunity Bank of Montana, today reported net income increased 98.9% to $5.1 million, or $1.32 per diluted share, in 2016, compared to $2.6 million, or $0.67 per diluted share, in 2015.  For the fourth quarter of 2016, net income increased 64.5% to $1.4 million, or $0.37 per diluted share, compared to $881,000, or $0.22 per diluted share, in the fourth quarter a year ago.  In the preceding quarter, Eagle earned a record $1.8 million, or $0.46 per diluted share. Eagle’s board of directors declared a regular quarterly cash dividend of $0.08 per share.  The dividend will be payable March 3, 2017 to shareholders of record February 10, 2017.  The current annualized yield is 1.63% at recent market prices. “We achieved record 2016 earnings, along with strong fourth quarter earnings of $1.4 million,” said Peter J. Johnson, President and CEO.  “We continue to produce solid loan and core deposit growth, which highlights our ability to deepen and grow customer relationships, as well as gain new customers and market share.  With steady balance sheet growth and significant and ongoing improvements in revenue generation, we are continuing to produce and retain earnings while paying appropriate dividends to increase value for our shareholders.” Fourth Quarter 2016 Highlights (at or for the three month period ended December 31, 2016, except where noted) “The loan portfolio continues to expand, which is a reflection of the strong local economy and demand in our markets.  The commercial real estate and C&I loan segments of our loan portfolio, in particular, continue to build momentum,” said Johnson.  Total loans increased 1.0% to $466.2 million at December 31, 2016, compared to $461.5 million three months earlier and increased 14.5% compared to $407.3 million a year earlier. Eagle originated $96.5 million in new residential mortgages during the quarter, excluding construction loans, and sold $90.6 million in residential mortgages, with an average gross margin on sale of mortgage loans of approximately 3.41%.  This production compares to residential mortgage originations of $101.2 million in the preceding quarter with sales of $95.6 million. Commercial real estate loans increased 28.0% to $214.9 million at December 31, 2016, compared to $167.9 million a year earlier, while residential mortgage loans decreased 4.1% to $113.3 million compared to $118.1 million a year earlier.  Commercial loans increased 40.0% to $54.7 million, home equity loans increased 8.1% to $49.0 million and construction loans decreased 10.5% to $20.5 million, compared to a year ago. Total deposits increased 6.1% to $512.8 million at December 31, 2016, compared to $483.2 million a year earlier but were down slightly compared to $515.3 million at September 30, 2016.  As of year-end, checking and money market accounts represent 51.8%, savings accounts represent 16.0%, and CDs comprise 32.2% of the total deposit portfolio. Eagle’s total assets increased 6.9% to $673.9 million at December 31, 2016, compared to $630.3 million a year earlier and decreased slightly compared to $674.5 million three months earlier.  Shareholders’ equity was $59.5 million at December 31, 2016, compared to $60.0 million three months earlier and increased 7.2% compared to $55.5 million one year earlier.  Tangible book value was $13.65 per share at December 31, 2016, compared to $13.91 per share at September 30, 2016, and $12.67 per share a year earlier. “Our 2016 net interest margin improved eight basis points to 3.46% compared to 3.38% in 2015, primarily as a result of growing both in core deposits and loans,” Johnson said.  Eagle’s net interest margin increased six basis point to 3.61% in the fourth quarter, compared to 3.55% in the preceding quarter and increased 20 basis point from 3.41% in the fourth quarter a year ago.  For the full year, Eagle’s net interest margin was 3.46% compared to 3.38% in 2015.  Funding costs for the fourth quarter were up two basis points while asset yields increased 22 basis points compared to a year ago.  The investment securities portfolio decreased to $128.4 million at December 31, 2016, compared to $145.7 million a year ago, which had a slight positive impact on the average yields on earning assets. Fourth quarter revenues increased 33.8% to $10.2 million compared to $7.6 million in the fourth quarter a year ago, and increased modestly compared to $10.1 million in the preceding quarter.  For the year, revenues increased 23.5% to $36.8 million, compared to $29.8 million in 2015.  Net interest income before the provision for loan loss increased 2.6% to $5.6 million in the fourth quarter compared to $5.4 million in the preceding quarter, and increased 14.3% compared to $4.9 million in the fourth quarter a year ago.  For the year, net interest income increased 15.4% to $20.8 million, compared to $18.0 million in 2015. Eagle’s noninterest income increased 70.8% to $4.6 million in the fourth quarter, compared to $2.7 million in the fourth quarter a year ago, but decreased modestly compared to $4.7 million in the preceding quarter.  For the full year, noninterest income increased 36.0% to $16.0 million compared to $11.8 million in 2015.  Mortgage servicing fees and net gain on sale of mortgage loans contributed to the growth.  Fourth quarter noninterest expenses were $7.6 million, compared to $7.2 million in the preceding quarter and $6.4 million in the year ago quarter.  Increased compensation due to additional loan production and year end benefit expenses contributed to the increase.  In 2016, noninterest expense was up modestly to $28.0 million compared to $25.7 million in 2015. Eagle’s fourth quarter provision for loan losses was $452,000, compared to $472,000 in the preceding quarter and $343,000 in the fourth quarter a year ago.  As of December 31, 2016, the allowance for loan losses represented 414.1% of nonperforming loans compared to 263.3% three months earlier and 139.3% a year earlier.  Nonperforming loans (NPLs) were $1.2 million at the end of the year, which was down 34.8% compared to $1.8 million three months earlier, and down 54.8% compared to $2.5 million a year earlier. Fourth quarter net charge-offs totaled $332,000, compared to $82,000 in the preceding quarter and $23,000 in the fourth quarter a year ago.  The allowance for loan losses was $4.8 million, or 1.02% of total loans at December 31, 2016, compared to $4.7 million, or 1.01% of total loans at September 30, 2016, and $3.6 million, or 0.87% of total loans a year ago. OREO and other repossessed assets was $825,000 at December 31, 2016, which was an increase compared to $513,000 at September 30, 2016.  Nonperforming assets (NPAs), consisting of nonperforming loans, OREO and other repossessed assets, loans delinquent 90 days or more, and restructured loans, improved to $2.0 million at December 31, 2016, or 0.29% of total assets, compared to $2.3 million, or 0.34% of total assets three months earlier and $3.1 million, or 0.50% of total assets a year earlier. Eagle Bancorp Montana continues to be well capitalized with the ratio of shareholders’ equity to tangible asset of 10.03% at December 31, 2016.  (Shareholders’ equity, plus trust preferred securities and subordinated debt, less goodwill and core deposit intangible to tangible assets). Eagle Bancorp Montana, Inc. is a bank holding company headquartered in Helena, Montana and is the holding company of Opportunity Bank, a community bank established in 1922 that serves consumers and small businesses in Montana through 13 banking offices. Additional information is available on the bank’s website at www.opportunitybank.com.  The shares of Eagle Bancorp Montana, Inc. are traded on the NASDAQ Global Select Market under the symbol “EBMT.” This release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," and "potential." These forward-looking statements include, but are not limited to statements of our goals, intentions and expectations; statements regarding our business plans, prospects, growth and operating strategies; statements regarding the asset quality of our loan and investment portfolios; and estimates of our risks and future costs and benefits. These forward-looking statements are based on current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. These factors include, but are not limited to, changes in laws or government regulations or policies affecting financial institutions, including changes in regulatory fees and capital requirements; general economic conditions, either nationally or in our market areas, that are worse than expected; competition among depository and other financial institutions; loan demand or residential and commercial real estate values in Montana; inflation and changes in the interest rate environment that reduce our margins or reduce the fair value of financial instruments; adverse changes in the securities markets; and other economic, governmental, competitive, regulatory and technological factors that may affect our operations. Because of these and other uncertainties, our actual future results may be materially different from the results indicated by these forward-looking statements. All information set forth in this press release is current as of the date of this release and the company undertakes no duty or obligation to update this information.


News Article | February 23, 2017
Site: www.eurekalert.org

During its 43rd Annual Meeting in Marseille, France, from 26th-29th March, the EBMT will hold a series of activities for its 5,000 delegates to celebrate 60 years of medical innovations saving patients' lives. The EBMT celebrates 60 years of medical innovations saving the lives of patients with blood cancers and other deadly diseases During its 43rd Annual Meeting in Marseille, France, from 26th-29th March, the EBMT will hold a series of activities for its 5,000 delegates to celebrate 60 years of medical innovations saving patients' lives. The EBMT will acknowledge the work that stems from the pioneering observations made by E. Donnall Thomas, also known as the father of bone marrow transplantation and who received the Nobel Prize in Medicine in 1990. For over 60 years Thomas' colleagues and fellows, not only in the United States but also in Europe and worldwide, have worked relentlessly in preclinical and clinical research to develop innovative treatments that improve the outcome and quality of life for cancer patients. This year marks the 60th anniversary of one of the seminal publications that triggered the introduction of haematopoietic stem cell transplantation (HSCT) in medical practices worldwide. This landmark paper by Thomas et al. entitled, "Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy" was published in the New England Journal on the 12th September 1957. The same year, this group also published other landmark papers in Blood. From the mid-1950s, Thomas developed methods for providing people with new bone marrow cells through transplants. Using radiation, chemotherapy, and nowadays immunosuppressive drugs, the body's own bone marrow cells are killed and the immune system's rejection mechanism is subdued. Bone marrow cells from a donor are then provided through a blood transfusion. In 1958, a year after Thomas' paper, Georges Mathé performed the first ever successful allogeneic bone marrow transplant on unrelated human beings. Since then, major developments in the field of HSCT have occurred thanks to the contributions of researchers worldwide. In fact, Nobel Prizes in physiology or medicine have been awarded for research in stem cells and transplantation: Jean Dausset, Baruj Benacerraf and Georges D. Snell in 1980 for the HLA histocompatibility system discovery; Joseph E. Murray and E. Donnall Thomas in 1990 for their discoveries concerning organ and cell transplantation for the treatment of human disease. The "EBMT's mission is very important and very ambitious," states Mohamad Mohty, President of the EBMT, and Head of the Haematology department at the Saint-Antoine Hospital in Paris. "Our goal is to conquer and cure blood diseases. In 1974, the visionary founders of the EBMT created one of the most successful medical societies in the world, and established a transplant registry that 43 years later includes 500,000 registered patients. The EBMT is in the privileged position of being always in the lead to disseminate knowledge, and advance the field of stem cell transplantation and cellular therapy" concludes Professor Mohty. While research is evolving, all eyes are turned towards novel cellular therapies for potential applications. Christian Chabannon, President of the 43rd EBMT Annual Meeting and Secretary of the Cellular Therapy and Immunobiology Working Party explains: "This denotes significant changes in the field, where medical practices evolve from the relatively monotypic approach of haematopoietic cell transplant to the more versatile use of different categories of cellular therapies." The EBMT's objective is to understand and exploit the biological, including immunological, events occurring upon HSCT at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes. At the Opening Session of the 43rd EBMT Annual Meeting, Rainer Storb from the faculty of both, the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, will give a keynote lecture entitled, "60 years of HSCT: progress from bone marrow transplantation to the first cellular and gene therapies." The EBMT is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives. The EBMT Members--more than 4,000 physicians, nurses, scientists and other healthcare professionals--participate in a unique collaborative network of peers involved in HSCT and cellular therapy research. The membership encompasses more than 600 centres, from over 60 countries, that perform or are involved in HSCT. The EBMT holds a central role in performing co-operative studies and disseminating state-of-the-art knowledge aimed at increasing survival rates and enhancing the quality of life of patients with life-threatening blood cancers and diseases. For further information about the EBMT, please visit the website: http://www. and follow us on Twitter: @TheEBMT

Loading EBMT collaborators
Loading EBMT collaborators